An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 to 60 Years.

Trial Profile

An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 to 60 Years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2012

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; MF 59
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 03 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Actual initiation date changed from Jan 2009 to Dec 2009 as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top